Cancer Biomarkers Guide

This content is brought to you by Abcam, a Danaher Operating Company.

Immunohistochemistry (IHC) is widely recognized as an invaluable tool in cancer research and remains a cornerstone in clinical diagnostics for cancer. Each cancer type is linked to specific protein biomarkers, which IHC can detect, providing a powerful approach for examining tumor development and responses. This technique enables researchers to trace the origin of tumors, determine tumor stages, forecast prognosis, and monitor therapeutic response. A clear understanding of each biomarker’s capabilities and limitations is crucial to prevent diagnostic inaccuracies, as no biomarker is exclusively specific to cancer.

ICH tests offer the advantages of being fast, reliable, straightforward, robust, and cost-effective compared to other diagnostic approaches. When paired with a quality biomarker panel, it becomes a highly effective method for rapid clinical diagnosis. Regardless of the cancer type, choosing an IHC antibody that is sensitive, consistent, and specific is a critical first step. This guide highlights several of the most common cancers, including breast, lung, colorectal, prostate, ovarian, and pancreatic, as well as a selection of established and emerging biomarkers for diagnosis, prognosis, and therapeutic monitoring. Identify the right biomarkers for your research, and find highly recommended antibodies for IHC applications.